Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
At NINGBO INNO PHARMCHEM CO.,LTD., we are dedicated to pioneering advancements in pharmaceutical science, with a strong focus on oncology. Our research efforts are directed towards developing highly effective and targeted therapies for various cancers, including colorectal cancer (CRC). Our latest breakthrough involves the development of SN38-glucose conjugates, a novel class of therapeutic agents designed to improve treatment outcomes.
The inherent metabolic characteristics of cancer cells, particularly their elevated glucose uptake, present a unique opportunity for targeted drug delivery. Cancer cells often overexpress glucose transporters (GLUTs) to fuel their rapid proliferation. NINGBO INNO PHARMCHEM CO.,LTD. is strategically leveraging this by synthesizing SN38-glucose conjugates. This approach exemplifies advanced glucose transporter targeted drug delivery, aiming to concentrate the potent anticancer drug SN38 within cancer cells while sparing healthy tissues. This targeted mechanism is crucial for improving drug efficacy and minimizing systemic toxicity.
Our extensive research has led to the successful synthesis and evaluation of several SN38-glucose conjugates. Among these, compound 5b has emerged as a particularly promising candidate. In vitro studies have demonstrated its potent antiproliferative activity against colorectal cancer cell lines, significantly outperforming existing treatments. Moreover, in vivo studies have confirmed its remarkable ability to inhibit tumor growth. The compound also shows potential in inducing apoptosis and inhibiting cancer cell migration, further solidifying its therapeutic value. These findings underscore the success of our novel SN38 glucose conjugates targeting cancer cells.
The development of effective anticancer agents for CRC treatment is a continuous pursuit, and our work with SN38-glucose conjugates represents a significant step forward. We are committed to innovation in novel anticancer compound synthesis, focusing on creating treatments that are both powerful and safe. The emphasis on selective chemotherapy for colorectal cancer ensures that our therapies offer superior benefits to patients.
NINGBO INNO PHARMCHEM CO.,LTD. is a leading provider of high-quality pharmaceutical intermediates and active pharmaceutical ingredients. We support researchers and manufacturers globally with our commitment to excellence and innovation. Our contributions to preclinical oncology drug development are driven by a vision to create a tangible impact on cancer care. We are always seeking collaborations to advance the field of oncology.
We invite you to partner with NINGBO INNO PHARMCHEM CO.,LTD. to explore the future of targeted cancer therapies. Together, we can make significant strides in improving patient outcomes and developing innovative treatments for colorectal cancer and beyond.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
